CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis
| Autor: | K. Voigt, C. Laske, T. Bregenzer, J. Tofighi, Jörg Kraus, N. Chatzimanolis, R. Bauer, Britta Engelhardt, Franz Blaes, B. S. Kuehne, Erwin Stolz, Manfred Kaps, Patrick Oschmann, Horst Traupe |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Multiple Sclerosis Lymphocyte Injections Subcutaneous Central nervous system disease Adjuvants Immunologic Antigens CD Recurrence medicine Humans Prospective cohort study Autoimmune disease Expanded Disability Status Scale medicine.diagnostic_test business.industry Multiple sclerosis Magnetic resonance imaging General Medicine Immunosenescence Interferon-beta Middle Aged medicine.disease Magnetic Resonance Imaging Lymphocyte Subsets Recombinant Proteins medicine.anatomical_structure Neurology Immunology Leukocyte Common Antigens Female Neurology (clinical) business Cell Adhesion Molecules Biomarkers Interferon beta-1b |
| Zdroj: | Acta neurologica Scandinavica. 110(6) |
| ISSN: | 0001-6314 |
| Popis: | Objectives– Multiple sclerosis (MS) is believed to be an autoimmune disease of the human central nervous system mediated by autoreactive T cells. Interferon-β1b (IFN-β1b) has been shown to be effective in reducing disease activity defined by clinical and magnetic resonance imaging (MRI) criteria in relapsing–remitting MS (RRMS). Yet, the exact mechanisms by which these benefits are achieved remain unknown. CD45RA is a marker for naive T lymphocytes and intercellular adhesion molecule-3 (ICAM-3) is expressed on resting lymphocytes. Material and methods– Forty-eight patients with RRMS, 24 of them treated with recombinant IFN-β1b and 24 untreated, were enrolled in this prospective study over 18 months. We investigated the percentage of CD45RA+ ICAM-3+ cells within the total lymphocyte subset in the peripheral blood serially every 3 months and in CSF once at baseline. Detailed clinical examination including Expanded Disability Status Scale (EDSS) score was performed every 3 months and cranial MRI scans were assessed every 6 months. Results– We found a temporary increase in the CD45RA+ ICAM-3+ lymphocyte ratio in peripheral blood of both untreated and IFN-β1b-treated RRMS patients. Moreover, we determined a significant negative correlation (r = −0.5874; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|